In order to promote the healthy development of my country's peptide industry and increase intra-industry exchanges. The Peptide Branch of the China Biochemical Pharmaceutical Industry Association will hold the "Third China Peptide Industry Conference and the Second Membership Conference of the Peptide Branch of the China Biochemical Pharmaceutical Industry Association" in Shenzhen from September 20 to 22, 2023.

At this conference,MOTIF will appear at booth C27,Welcome to visit and exchange!

The conference will create a full-industry chain exchange and cooperation model supported by industry, multi-disciplinary cross-integration, close integration within the industry, and linkage with capital parties. It is planned to invite leaders of relevant national ministries and commissions, relevant drug supervision and inspection institutions, experts, scholars, and enterprises in the field of peptides Researchers from the upstream and downstream R&D, production and sales enterprises of the peptide industry, as well as universities and scientific research institutes, brought together the elite backbones of the "industry, academia, research, application, management and investment" to make suggestions for the development of China's peptide industry.The conference will have one main venue and two sub-venues, covering cutting-edge research, quality standards, production processes, clinical applications and localization of the peptide industry, and exploring paths and countermeasures to promote high-end growth in strategic emerging industries.

"Successful customers, successful employees, successful company" are Merdiv's eternal values.In the future, Merdiv will extend the industrial chain based on peptide CRO and CDMO, actively explore peptide-related technology licensing platforms for PDC and ADC drugs, CRO and CDOM R&D platforms for nucleic acid drugs, and further expand R&D and production capacity. to more than 100 kilograms, forming a R&D, production and sales platform for all types of peptides, and becoming a benchmark enterprise in the global peptide drug CDMO business.